BOOM
AI Engines For more Details: Perplexity Kagi Labs You
| Rank | Probitoic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Increases |
| species | Bacteroides uniformis | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | -0.2 | |
| Acne | 0.5 | 0.9 | -0.8 |
| ADHD | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.6 | -1 |
| Allergies | 1.8 | 0.8 | 1.25 |
| Allergy to milk products | 0.6 | 1.2 | -1 |
| Alopecia (Hair Loss) | 0.5 | 0.1 | 4 |
| Alzheimer's disease | 2.9 | 2.1 | 0.38 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 1.7 | -1.83 |
| Ankylosing spondylitis | 0.6 | 1.7 | -1.83 |
| Anorexia Nervosa | 0.8 | 0.8 | |
| Antiphospholipid syndrome (APS) | 0.8 | 0.2 | 3 |
| Asthma | 1.5 | 1.1 | 0.36 |
| Atherosclerosis | 2.2 | 0.8 | 1.75 |
| Atrial fibrillation | 1.1 | 0.8 | 0.38 |
| Autism | 1.7 | 2 | -0.18 |
| Autoimmune Disease | 0.5 | 0.5 | |
| Barrett esophagus cancer | 0.5 | 0.5 | |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Bipolar Disorder | 0.3 | 0.6 | -1 |
| Brain Trauma | 0.6 | 0.6 | |
| Cancer (General) | 0.1 | 0.1 | |
| Carcinoma | 0.6 | 0.6 | 0 |
| Celiac Disease | 1.9 | 1.1 | 0.73 |
| Cerebral Palsy | 0.6 | 0.9 | -0.5 |
| Chronic Fatigue Syndrome | 0.6 | 1.3 | -1.17 |
| Chronic Kidney Disease | 0.3 | 0.7 | -1.33 |
| Chronic Lyme | 0.6 | 0.6 | |
| Chronic Urticaria (Hives) | 0.8 | 0.8 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | 0.5 | |
| Cognitive Function | 0.9 | -0.9 | |
| Colorectal Cancer | 2.7 | 2 | 0.35 |
| Constipation | 0.9 | -0.9 | |
| Coronary artery disease | 1.3 | 1.3 | |
| COVID-19 | 3.5 | 3.3 | 0.06 |
| Crohn's Disease | 2 | 1.8 | 0.11 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | 0.6 | |
| cystic fibrosis | 0.6 | 0.6 | |
| deep vein thrombosis | 1.1 | 0.5 | 1.2 |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 1.9 | 3 | -0.58 |
| Eczema | 0.2 | 0.3 | -0.5 |
| Endometriosis | 0.6 | -0.6 | |
| Eosinophilic Esophagitis | 0.5 | 0.5 | |
| Epilepsy | 1.5 | 1.1 | 0.36 |
| erectile dysfunction | 0.6 | 0.6 | 0 |
| Fibromyalgia | 1.4 | 1.4 | |
| Functional constipation / chronic idiopathic constipation | 1.4 | 1.3 | 0.08 |
| gallstone disease (gsd) | 0.8 | 0.2 | 3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.6 | 0.7 | 1.29 |
| Generalized anxiety disorder | 1.1 | 0.9 | 0.22 |
| Gout | 0.8 | 1.9 | -1.37 |
| Graves' disease | 1.4 | 0.6 | 1.33 |
| Gulf War Syndrome | 1.2 | 0.3 | 3 |
| Halitosis | 1 | 0.6 | 0.67 |
| Hashimoto's thyroiditis | 1.4 | 1.1 | 0.27 |
| Heart Failure | 1.3 | 0.6 | 1.17 |
| Hidradenitis Suppurativa | 0.6 | -0.6 | |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 2 | 2 | |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypertension (High Blood Pressure | 1.5 | 2 | -0.33 |
| Hypothyroidism | 0.5 | 0.9 | -0.8 |
| Hypoxia | 1.7 | -1.7 | |
| IgA nephropathy (IgAN) | 1.9 | 0.6 | 2.17 |
| Inflammatory Bowel Disease | 2.2 | 1.5 | 0.47 |
| Insomnia | 1.9 | 0.6 | 2.17 |
| Intelligence | 0.8 | -0.8 | |
| Intracranial aneurysms | 0.6 | -0.6 | |
| Irritable Bowel Syndrome | 2.5 | 2.2 | 0.14 |
| ischemic stroke | 1.6 | 1.2 | 0.33 |
| Liver Cirrhosis | 1.5 | 1.1 | 0.36 |
| Long COVID | 1.3 | 1.4 | -0.08 |
| Lung Cancer | 0.6 | 0.1 | 5 |
| Mast Cell Issues / mastitis | 0.5 | 0.5 | |
| ME/CFS with IBS | 0.6 | 0.6 | |
| ME/CFS without IBS | 0.6 | 0.6 | |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 2.4 | 1.7 | 0.41 |
| Mood Disorders | 1.9 | 3.6 | -0.89 |
| multiple chemical sensitivity [MCS] | 0.3 | -0.3 | |
| Multiple Sclerosis | 0.8 | 0.9 | -0.13 |
| Multiple system atrophy (MSA) | 0.9 | -0.9 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.9 | 0.9 | |
| Neuropathy (all types) | 1.1 | 0.3 | 2.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | -0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 0.8 | 2.13 |
| NonCeliac Gluten Sensitivity | 0.6 | 1.2 | -1 |
| Obesity | 3 | 1.5 | 1 |
| obsessive-compulsive disorder | 1.2 | 1.2 | 0 |
| Osteoarthritis | 0.9 | 0.8 | 0.13 |
| Osteoporosis | 1.7 | 0.6 | 1.83 |
| pancreatic cancer | 0.6 | 0.6 | |
| Parkinson's Disease | 1.6 | 2 | -0.25 |
| Polycystic ovary syndrome | 1.2 | 1.1 | 0.09 |
| primary biliary cholangitis | 0.2 | 0.2 | |
| Primary sclerosing cholangitis | 0.6 | -0.6 | |
| Psoriasis | 1.7 | 0.5 | 2.4 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 1.2 | 0.58 |
| Rosacea | 0.5 | 0.5 | |
| Schizophrenia | 1.2 | 1.4 | -0.17 |
| Sjögren syndrome | 0.8 | 0.5 | 0.6 |
| Sleep Apnea | 0.6 | 0.6 | |
| Slow gastric motility / Gastroparesis | 0.6 | -0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | -0.6 | |
| Stress / posttraumatic stress disorder | 1.3 | 0.9 | 0.44 |
| Systemic Lupus Erythematosus | 1.1 | -1.1 | |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 1.4 | 1.6 | -0.14 |
| Type 2 Diabetes | 2.1 | 1.5 | 0.4 |
| Ulcerative colitis | 3.6 | 1.1 | 2.27 |
| Unhealthy Ageing | 0.3 | 0.8 | -1.67 |
| Vitiligo | 0.3 | 0.8 | -1.67 |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
